IFNg-activated dermal lymphatic vessels restrict anti-tumor immunity

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Associate Professor, Ronald O. Perelman Department of Dermatology and Pathology; NYU Grossman School of Medicine Member, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health
    BIOGRAPHY

Abstract

Mechanisms of immune suppression in peripheral tissues counteract protective immunity to prevent immunopathology and are coopted by tumors for immune escape. While lymphatic vessels facilitate T cell priming through dendritic cell and antigen delivery to lymph nodes, they also exert PD-L1-dependent immune suppressive effects in lymph nodes at steady state, and facilitate melanoma metastasis. How lymphatic vessels may switch between immunogenic and immune suppressive roles remains and area of active investigation. Here we demonstrate a specific role for non-hematopoietic, non-tumor PD-L1, in limiting CD8+ T cell accumulation in melanoma. We find that IFNg produced by tissue infiltrating, antigen-specific CD8+ T cells is sufficient to activate lymphatic vessel PD-L1 expression. As such, disruption of IFNg-dependent crosstalk through lymphatic-specific loss of IFNγR boosts T cell accumulation in melanoma leading to CD8+ T cell-mediated tumor control and improved overall survival. Importantly, robust lymphatic vessel-dependent tumor control was revealed in the context of murine melanomas with significant UVB-induced somatic mutation burden, consistent with our model of cytotoxic T cell-activated mechanisms of negative feedback. Consequently, we present IFNg-mediated activation of tumor-associated lymphatic vessels as an important immunological switch in skin and tumors that contributes to adaptive immune resistance. We suggest that a continued understanding of context-dependent lymphatic vessel function will to reveal novel mechanisms of immune control and metastasis in melanoma.

Learning Objectives:

1. Define the impact of PD-L1 expressed on non-tumor, non-hematopoietic cells in T cell-mediated tumor control

2. Reveal the contribution of IFNg signaling in dermal lymphatic vessels to tumor control

3. Explain the contribution of adaptive immune resistance to immunotherapy response


Show Resources
You May Also Like
SEP 14, 2021 7:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
APR 21, 2021 10:00 AM PDT
C.E. CREDITS
APR 21, 2021 10:00 AM PDT
Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
FEB 24, 2021 10:00 AM PST
C.E. CREDITS
FEB 24, 2021 10:00 AM PST
DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
JUN 03, 2021 12:00 PM CST
JUN 03, 2021 12:00 PM CST
DATE: June 3, 2021 TIME: 12:00pm SGT This webinar is a virtual event that focuses on utilizing the Gibco CTS Rotea System for Cell and Gene Therapy...
Loading Comments...
Show Resources